The potential therapeutic benefit of an anti-ALK immune response has been demonstrated in a mouse model of ALK-positive ALCL, in which a DNA-based ALK vaccine was shown to generate ALK-specific cytotoxic T-cell responses and protect mice from developing lymphoma [15]. Here, ALK is linked to lymphoma.